Skip to content
Screener

Neuropace, Inc. NPCE Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

LivaNova logo
LivaNovaLIVN
$56.71M+11.9%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$13.09M+342%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$23.07M-7.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$8.73M-21.0%
CVRx, Inc. logo
CVRx, Inc.CVRX
$708K-32.4%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$5.39M-26.1%

Other financials

Income statement

See full
Revenue$22.8M+17.1%
Gross profit$18.9M+16.6%
Operating income-$5.1M+37.2%
Net income-$6.2M+28.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$12.8M-44.4%
Total debt$69.9M-2.2%
Total equity$11.9M-38.9%
Total assets$97.0M-8.6%

Cash flow

See full
Operating cash flow-$3.9M-87.1%
CapEx$125.0K-25.6%
Free cash flow-$4.0M-78.7%

Valuation

See full
Market cap$507.31M+74.0%
Enterprise value$564.47M+66.0%
P/S5.1×+1.7×

Profitability

See full
Gross margin79.6%+2.6pp
Operating margin-15.3%-4.3pp
Net margin-19.3%-5.2pp
FCF margin-12.2%-3.3pp

Returns & leverage

See full
Return on equity-122.1%-28.9pp
Debt / equity5.9×+2.2×
Current ratio4.9×-0.5×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:33 PM EDT
Fiscal quarter
Q4 FY2030
Calendar quarter
Q4 2030
Accession
0001528287-26-000030

Operating lease cost was $0.7 million for each of the three months ended June 30, 2026 and 2025. Operating lease cost was $1.4 million for each of the six months ended June 30, 2026 and 2025. As of June 30, 2026, the remaining term for the operating lease in Mountain View, California was 4 years, and the discount rate used to measure the lease liability for such operating lease upon recognition was 8.5%.

Item 1. Financial Statements (Unaudited)

FAQ

What is Neuropace, Inc.'s operating lease ROU assets?
Neuropace, Inc. (NPCE) reported operating lease ROU assets of 8.5% in Q2 2026.
How has Neuropace, Inc.'s operating lease ROU assets changed year-over-year?
Neuropace, Inc.'s operating lease ROU assets decreased by 0.0% year-over-year, from 8.5% to 8.5%.
What is the long-term trend for Neuropace, Inc.'s operating lease ROU assets?
Over 3 years (2022 to 2025), Neuropace, Inc.'s operating lease ROU assets has grown at a 0.0% compound annual growth rate (CAGR), from 8.5% to 8.5%.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Neuropace, Inc.'s operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude